Ruxolitinib
Ruxolitinib
Ruxolitinib (pronounced rooks-oh-LIT-in-ib) is a medication used in the treatment of certain types of cancer and myelofibrosis, a serious bone marrow disorder. It is marketed under the brand names Jakafi and Jakavi.
Etymology
The name Ruxolitinib is derived from its chemical structure. The "Ruxo" part of the name is a reference to its chemical class, while the "itinib" suffix is common in drugs that inhibit specific enzymes.
Usage
Ruxolitinib is a Janus kinase inhibitor, which works by blocking certain enzymes in the body that affect blood cell production. It is used to treat myelofibrosis and polycythemia vera, which are bone marrow disorders that affect your body's ability to produce blood cells. It is also used to treat a certain type of acute graft versus host disease (GVHD) in adults and children who are at least 12 years old.
Side Effects
Common side effects of Ruxolitinib include anemia, thrombocytopenia, bruising, dizziness, and headache. Serious side effects may include infections, cancer, and a decrease in blood cell counts.
Related Terms
- Janus kinase inhibitor
- Myelofibrosis
- Polycythemia vera
- Acute graft versus host disease
- Anemia
- Thrombocytopenia
External links
- Medical encyclopedia article on Ruxolitinib
- Wikipedia's article - Ruxolitinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski